Andere Kunden interessierten sich auch für
![Mantle Cell Lymphoma, an Issue of Hematology/Oncology Clinics of North America]( "Mantle Cell Lymphoma, an Issue of Hematology/Oncology Clinics of North America")
Mantle Cell Lymphoma, an Issue of Hematology/Oncology Clinics of North America69,99 €![T-Cell Lymphoma, an Issue of Hematology/Oncology Clinics of North America]( "T-Cell Lymphoma, an Issue of Hematology/Oncology Clinics of North America")
T-Cell Lymphoma, an Issue of Hematology/Oncology Clinics of North America69,99 €![Follicular Lymphoma, an Issue of Hematology/Oncology Clinics of North America]( "Follicular Lymphoma, an Issue of Hematology/Oncology Clinics of North America")
Follicular Lymphoma, an Issue of Hematology/Oncology Clinics of North America69,99 €![Non-Hodgkin's Lymphoma, an Issue of Hematology/Oncology Clinics of North America]( "Non-Hodgkin's Lymphoma, an Issue of Hematology/Oncology Clinics of North America")
Non-Hodgkin's Lymphoma, an Issue of Hematology/Oncology Clinics of North America69,99 €![Hodgkin's Lymphoma, an Issue of Hematology/Oncology Clinics]( "Hodgkin's Lymphoma, an Issue of Hematology/Oncology Clinics")
Hodgkin's Lymphoma, an Issue of Hematology/Oncology Clinics59,99 €![Cutaneous Lymphoma, an Issue of Dermatologic Clinics]( "Cutaneous Lymphoma, an Issue of Dermatologic Clinics")
Cutaneous Lymphoma, an Issue of Dermatologic Clinics57,99 €![The Treatment of Myeloid Malignancies with Kinase Inhibitors, an Issue of Hematology/Oncology Clinics of North America]( "The Treatment of Myeloid Malignancies with Kinase Inhibitors, an Issue of Hematology/Oncology Clinics of North America")
The Treatment of Myeloid Malignancies with Kinase Inhibitors, an Issue of Hematology/Oncology Clinics of North America69,99 €
This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; The grey zone of unclassifiable lymphomas; as well as many more.